Full-Time

Senior Director Global Regulatory Lead

Late Phase, Diabetes and Obesity

Posted on 9/2/2025

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$162k - $237.6k/yr

+ Bonus

Indianapolis, IN, USA

In Person

Relocation is provided.

Category
Legal & Compliance (2)
,
Required Skills
Risk Management
Requirements
  • Advanced scientific degree (i.e., PhD, PharmD) and 8+ years Industry-related experience in regulatory affairs and/or drug development experience
  • OR
  • Bachelor’s with 10+ years of industry-related experience in regulatory affairs and/or drug development experience
  • Proven experiences and leadership assignments demonstrating bold leadership, effective communications with peers and executive leaders, and effective conflict management skills
  • Experience in regulatory submissions and regulatory interactions in the US, EU, China and Japan
  • Previous regulatory or leadership assignments across multiple countries
  • Industry-related experience in regulatory affairs and/or drug development experience for 10 years
  • Direct experience in clinical and CMC regulatory sciences
  • Experience in applicable therapeutic area
  • Knowledge of Global regulatory procedures and practices and awareness of evolving regulatory reform initiatives desirable
  • Demonstrated deep knowledge of the integrated drug development process and regulatory/business strategies
  • Demonstrated ability to find solutions and alternatives through teamwork embracing inclusion resulting in positive business outcomes
  • Strong written, spoken and presentation communication
  • Demonstrated ability to assess and manage risk in a highly regulated environment, attention to detail, negotiation and influence skills
Responsibilities
  • Develop, Update and Implement the Global Regulatory Strategy - Initiate and Update Regulatory Strategy Document (RSD)
  • Acquire input from the global regulatory team members to develop a global regulatory strategy which supports product (including delivery device and relevant medical devices) development, registration, and lifecycle maintenance globally.
  • Lead Global Regulatory Team in the development of RSD(s) for assigned programs.
  • Provide input for and attend key regulatory agency meetings, as needed, that could impact the global product strategy or brand.
  • Enable discussion of the RSD and regulatory issues/challenges at the Regulatory Strategy Forum together with Global Regulatory Team.
  • Ensure strategic messaging and content of global regulatory submission documents.
  • Provide timely and effective communication updates to the GBD teams and BU management and other internal stakeholders.
  • Lead Global Regulatory Team consisting of regional regulatory scientists, GRA-CMC, GRA-Devices, GRA-RD&E, and GRA-Global Labeling and Product Communications.
  • Communicate and share key information to enable seamless execution of global regulatory strategy and cross-functional shared learnings.
  • Represent Regulatory on the GBD/Global Program Team
  • Support development teams in strategic planning, trial design and registration strategies for all in-scope countries for assigned products/programs.
  • Consistently communicate well defined, successful regulatory strategies throughout the organization.
  • Engage in, influence, and shape external environment initiatives related to portfolio assets.
  • Creates and fosters strategic relationships with key external players to identify and anticipate opportunities for growth.
  • Review corporate communications press releases.
  • Set appropriate direction with Global Marketing and GBD team for development, review, and approval of promotional claims.
Desired Qualifications
  • Experience in applicable therapeutic area
  • Anticipated travel of 10-15%

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Medicare's GLP-1 Bridge can broaden access to Mounjaro and Zepbound.
  • CVS restored Zepbound coverage and added Foundayo across major formularies.
  • Lilly can redeploy capital from Germany toward U.S. manufacturing expansion.

What critics are saying

  • Medicare's bridge program compresses pricing and shifts volume from premium channels.
  • CVS can re-prefer Wegovy or exclude obesity drugs entirely on sponsor opt-outs.
  • Lilly's tirzepatide concentration makes any safety, supply, or pricing shock severe.

What makes Lilly USA unique

  • Lilly dominates diabetes and obesity with Mounjaro and Zepbound, driving 56% revenue.
  • The company pairs blockbuster commercialization with deep R&D and global manufacturing scale.
  • Recent acquisitions add vaccines and non-viral genetic medicine platforms beyond GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-5%

2 year growth

-5%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE